

Publikacje naukowe zespołu SDS Optic S.A.

Publikacje naukowe

1. Wysokiński K, Budnicki D, Fidelus J, Szostkiewicz Ł, Ostrowski Ł, Murawski M, Staniszewski M, Staniszewska M, Napierała M, Nasiłowski T. Dual-core all-fiber integrated immunosensor for detection of protein antigens. Biosens Bioelectron. 2018 Aug 30;114:22-29. doi: 10.1016/j.bios.2018.05.008. Epub 2018 May 9. PubMed PMID: 29775855.
2. Tkaczuk-Włach J, Kędzierski W, Jonik I, Sadok I, Filip A, Kankofer M, Polkowski W, Ziółkowski P, Gamian A, Staniszewska M. Immunomodulatory Factors in Primary Endometrial Cell Cultures Isolated from Cancer and Noncancerous Human Tissue-Focus on RAGE and IDO1. Cells. 2021 Apr 25;10(5). doi: 10.3390/cells10051013. PubMed PMID: 33922995; PubMed Central PMCID: PMC8145962.
3. Kuźmicz-Mirośław E, Kuśmierz M, Terpiłowski K, Śmietana M, Barczak M, Staniszewska M. Effect of Various Surface Treatments on Wettability and Morphological Properties of Titanium Oxide Thin Films. Materials (Basel). 2022 Jun 9;15(12). doi: 10.3390/ma15124113. PubMed PMID: 35744176; PubMed Central PMCID: PMC9227497.
4. Antos A, Topolska-Woś A, Woś M, Mitura A, Sarzyńska P, Lipiński T, Kurylcio A, Ziółkowski P, Świtalska M, Tkaczuk-Włach J, Gamian A, Polkowski WP, Staniszewska M. The unique monoclonal antibodies and immunochemical assay for comprehensive determination of the cell-bound and soluble HER2 in different biological samples. Sci Rep. 2024 Feb 17;14(1):3978. doi: 10.1038/s41598-024-54590-z. PubMed PMID: 38368450; PubMed Central PMCID: PMC10874376.

Abstrakty

1. [Glycation status in breast and endometrial tumors assessed based on the expression of MAGE – the novel glycation end-products and RAGE – receptor for advanced glycation-end products](#)
EORTC-NCI-AACR
M. Staniszewska | K. Gostomska-Pampuch | P. Ziółkowski | A. Gamian
2. [Tailoring the Diagnostic Pathway in Patients with Gastric Cancer \(GC\) Using the Innovative inPROBE® Technology Platform to Assess HER2 Expression in Peritoneal Lavage: A Pilot Study](#)
EORTC-NCI-AACR
D. Stencel | Zuzanna Pelc | Katarzyna Sędkak | Karol Rawicz-Pruszyński | D. Lenart | M. Staniszewski | M. Staniszewska
3. [Is HER2-negative breast cancer really negative? Clinical implication of novel assessment method using inPROBE technology](#)
ASCO
Dariusz M. Stencel | Wojciech Polkowski | Andrzej Kurylcio | Przemysław Kopyto | Marcin Staniszewski | Magdalena Staniszewska
4. [Innovative fiber optic-based approach of HER2 expression quantitative assessment using inPROBE technology](#)
ASCO
Dariusz M. Stencel | Marcin Staniszewski | Wojciech Polkowski | Andrzej Kurylcio | Przemysław Kopyto | Magdalena Staniszewska
5. [Novel in vivo photonics-immunoassay system, inPROBE, for the rapid detection of HER2 in breast cancer](#)
ESMO
A. Kurylcio | K. Sędkak | W.P. Polkowski | M. Śmietana | M. Staniszewski
6. [HER2 distribution in tumor and blood of mice with xenograft human cancer](#)
[EORTC-NCI-AACR](#)
A. Antos | M. Świtalska | A. Topolska-Woś | M. Woś1 | A. Mitura | M. Staniszewska

Prezentacje posterowe

1. Tkaczuk-Wlach J, Kedzierski W, Jonik I, Sadok I, Putowski L, Kankofer M, Staniszevska M, Primary culture of human endometrial cells as a model to study tissue-released immunoregulatory factors, November 23 – 25, 2018, 26th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI), London, UK
2. Antos A, Świtalska M, Topolska-Woś A, Wos M, Mitura A, Staniszevska M, HER2 distribution in tumour and blood of mice with xenograft human cancer, *European Journal of Cancer* 174S1 (2022) S3–S128
3. Staniszevska M, Kurylcio A, Sędkak K, Polkowski WP, Smietana M, Staniszevski M, Novel in vivo photonics-immunoassay system, inPROBE, for the rapid detection of HER2 in breast cancer, European Society of Molecular Oncology (ESMO) Congress, 20-24 October 2023, Madrid, Spain, *Annals of Oncology*, Vol. 34, Supplement S718, October, 2023
4. Stencel D, Polkowski W, Kopyto P, Kurylcio A, Staniszevski M, Staniszevska M, Is HER2-negative breast cancer really negative? Clinical implication of novel assessment method using inPROBE technology.
Publ.: *Journal of Clinical Oncology*, Vol. 42, Number 16 suppl., October 25, 2024 doi.org/10.1200/JCO.2024.42.16_suppl.e13030
5. D. Stencel, Z. Pelc, K. Sędkak, K. Rawicz-Pruszyński, D. Lenart, M. Staniszevski, M. Staniszevska, Tailoring the Diagnostic Pathway in Patients with Gastric Cancer (GC) Using the Innovative inPROBE® Technology Platform to Assess HER2 Expression in Peritoneal Lavage: A Pilot Study, *European Journal of Cancer* 211S1 (2024) 114723 <https://10.1016/j.ejca.2024.114723>
6. D. Stencel, W.P. Polkowski, M. Staniszevska, M. Staniszevski, A. Kurylcio, Phase I/II clinical trial with innovative HER2 expression assessment inPROBE technology, Proceedings of the 2024 San Antonio Breast Cancer Symposium; 2024 Dec 10-13; San Antonio, TX.; 2024. Abstract nr 7705, SABC2024, San Antonio, TX, USA,

Badania kliniczne

1. SDS Optic S.A., Safety and Efficacy Assessment of Diagnostic Microprobe (inPROBE) in Women at High Risk of Breast Cancer, 2022, clinicaltrials.gov NCT05415943

